FcResolv® NOG Strains: Eliminating Murine Fc Gamma Receptor Interference in Antibody-Based Drug Discovery
Murine Fc gamma receptors (FcγRs) in preclinical models pose significant challenges in the evaluation of antibody-based therapies, often leading to misleading outcomes that can derail drug discovery. The novel FcResolv® NOG model portfolio is designed to target the knockout of these receptors to eliminate significant confounding variables and improve the accuracy of antibody-based drug studies.
Discover how super immunodeficient FcResolv® NOG mice are offering researchers greater confidence and more translatable data while utilizing fewer resources. In this webinar, Dr. Ditte Olsen dives into the FcResolv® NOG portfolio, including the super immunodeficient FcResolv® NOG strain, strains that express human cytokines on the FcResolv® NOG background in order to support certain human immune cells, and several humanized immune system (HIS) FcResolv® NOG models. Get insight into the utility of these innovative models for research involving antibody-based therapeutics.
Watch this webinar to:
- Discover how the FcResolv® NOG Portfolio extends the utility of the widely used super immunodeficient CIEA NOG mouse® by eliminating murine Fc gamma receptors known to derail antibody-based drug discovery
- Understand how researchers avoid wasteful investments based on false positives or missing out on a promising candidate due to false negatives
- Learn how FcResolv® NOG mice are suited to a range of applications, particularly tumor xenografts, cell and tissue engraftment, and drug efficacy studies with antibody-based therapeutics
- Get insight into the newest additions to the FcResolv® NOG portfolio, including a humanized immune system (HIS) model supporting human myeloid and lymphoid cells - the FcResolv® huNOG-EXL
Watch the Webinar
Ditte Olsen, PhD
Field Applications Scientist | Taconic Biosciences
Dr. Ditte Olsen received her Master of Science in Molecular Biology from Aarhus University, Denmark and earned her industrial PhD in Neuroscience from Aarhus University and Lundbeck.
During her PhD, Ditte studied the dopaminergic system in various transgenic animal models. During her postdoctoral training, her focus changed to the field of cardiovascular disorders.
Following her postdoctoral training, she joined a biotech company where her focus was on preclinical research using small molecules to reduce high cholesterol levels. Ditte brings nearly 15 years of in vivo research experience to her role as a Field Applications Scientist at Taconic.